Login to Your Account



Celgene snags Beigene PD-1 inhibitor for $413M up front and up to $980M in milestones

By Michael Fitzhugh
Staff Writer

Wednesday, July 12, 2017

A new deal giving Celgene Corp. strategically important rights to a PD-1 inhibitor developed by Beijing-based Beigene Ltd. will tightly bond the companies' fortunes in both the U.S. and China, putting Celgene in charge of development and commercialization of a key Beigene asset, while Beigene takes charge of selling Celgene's top products in China and advancing new ones.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription